Usefulness of serum-ascites albumin difference in separating transudative from exudative ascites - Another look

Kenneth Mauer, Nancy C. Manzione

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The serumascites albumin difference is reported to be superior to ascitic total protein, ascitic-to-serum total protein ratio, lactic dehydrogenase, and ascitic-to-serum lactic dehydrogenase ratio in differentiating between ascites from liver disease and malignant ascites, S-A>1.1 reflecting portal hypertension. We analyzed ascitic fluid from 46 consecutive patients with chronic liver disease, 28 patients with ascites associated with malignancy, 10 patients with rightsided heart failure, 4 patients with hypothyroidism, and 6 patients with miscellaneous causes of ascites to determine if this albumin difference is indeed a more valuable parameter. Analysis of our data confirms with a larger number of patients that the serum-ascites albumin difference is a more reliable indicator of transudative ascites, better termed portal hypertensive ascites. Malignant ascites without liver metastases had features of nonportal hypertensive ascites, and the serum-ascites albumin difference confirms this. The characteristics of malignant ascites associated with liver metastases, however, resemble those of the portal hypertensive ascites complicating liver disease. This new parameter is also helpful in distinguishing congestive heart failure with high protein ascites and portal hypertensive ascitic features from malignant ascites without liver metastases. Of particular note, myxedematous ascitic fluid, classically categorized as exudative, had an S-A>1.1, indicating the possible role of portal hypertension in the development of ascites in these patients.

Original languageEnglish (US)
Pages (from-to)1208-1212
Number of pages5
JournalDigestive Diseases and Sciences
Volume33
Issue number10
DOIs
StatePublished - Oct 1988

Fingerprint

Ascites
Serum Albumin
Liver Diseases
Ascitic Fluid
Portal Hypertension
Neoplasm Metastasis
Albumins
Liver
Oxidoreductases
Milk
Heart Failure
Hypothyroidism
Blood Proteins
Proteins
Chronic Disease

Keywords

  • ascites, serum-ascites albumin difference
  • exudate
  • myxedematous ascites
  • transudate

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Usefulness of serum-ascites albumin difference in separating transudative from exudative ascites - Another look. / Mauer, Kenneth; Manzione, Nancy C.

In: Digestive Diseases and Sciences, Vol. 33, No. 10, 10.1988, p. 1208-1212.

Research output: Contribution to journalArticle

@article{99e038a0fd3241c6975e4cadc54340eb,
title = "Usefulness of serum-ascites albumin difference in separating transudative from exudative ascites - Another look",
abstract = "The serumascites albumin difference is reported to be superior to ascitic total protein, ascitic-to-serum total protein ratio, lactic dehydrogenase, and ascitic-to-serum lactic dehydrogenase ratio in differentiating between ascites from liver disease and malignant ascites, S-A>1.1 reflecting portal hypertension. We analyzed ascitic fluid from 46 consecutive patients with chronic liver disease, 28 patients with ascites associated with malignancy, 10 patients with rightsided heart failure, 4 patients with hypothyroidism, and 6 patients with miscellaneous causes of ascites to determine if this albumin difference is indeed a more valuable parameter. Analysis of our data confirms with a larger number of patients that the serum-ascites albumin difference is a more reliable indicator of transudative ascites, better termed portal hypertensive ascites. Malignant ascites without liver metastases had features of nonportal hypertensive ascites, and the serum-ascites albumin difference confirms this. The characteristics of malignant ascites associated with liver metastases, however, resemble those of the portal hypertensive ascites complicating liver disease. This new parameter is also helpful in distinguishing congestive heart failure with high protein ascites and portal hypertensive ascitic features from malignant ascites without liver metastases. Of particular note, myxedematous ascitic fluid, classically categorized as exudative, had an S-A>1.1, indicating the possible role of portal hypertension in the development of ascites in these patients.",
keywords = "ascites, serum-ascites albumin difference, exudate, myxedematous ascites, transudate",
author = "Kenneth Mauer and Manzione, {Nancy C.}",
year = "1988",
month = "10",
doi = "10.1007/BF01536667",
language = "English (US)",
volume = "33",
pages = "1208--1212",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "10",

}

TY - JOUR

T1 - Usefulness of serum-ascites albumin difference in separating transudative from exudative ascites - Another look

AU - Mauer, Kenneth

AU - Manzione, Nancy C.

PY - 1988/10

Y1 - 1988/10

N2 - The serumascites albumin difference is reported to be superior to ascitic total protein, ascitic-to-serum total protein ratio, lactic dehydrogenase, and ascitic-to-serum lactic dehydrogenase ratio in differentiating between ascites from liver disease and malignant ascites, S-A>1.1 reflecting portal hypertension. We analyzed ascitic fluid from 46 consecutive patients with chronic liver disease, 28 patients with ascites associated with malignancy, 10 patients with rightsided heart failure, 4 patients with hypothyroidism, and 6 patients with miscellaneous causes of ascites to determine if this albumin difference is indeed a more valuable parameter. Analysis of our data confirms with a larger number of patients that the serum-ascites albumin difference is a more reliable indicator of transudative ascites, better termed portal hypertensive ascites. Malignant ascites without liver metastases had features of nonportal hypertensive ascites, and the serum-ascites albumin difference confirms this. The characteristics of malignant ascites associated with liver metastases, however, resemble those of the portal hypertensive ascites complicating liver disease. This new parameter is also helpful in distinguishing congestive heart failure with high protein ascites and portal hypertensive ascitic features from malignant ascites without liver metastases. Of particular note, myxedematous ascitic fluid, classically categorized as exudative, had an S-A>1.1, indicating the possible role of portal hypertension in the development of ascites in these patients.

AB - The serumascites albumin difference is reported to be superior to ascitic total protein, ascitic-to-serum total protein ratio, lactic dehydrogenase, and ascitic-to-serum lactic dehydrogenase ratio in differentiating between ascites from liver disease and malignant ascites, S-A>1.1 reflecting portal hypertension. We analyzed ascitic fluid from 46 consecutive patients with chronic liver disease, 28 patients with ascites associated with malignancy, 10 patients with rightsided heart failure, 4 patients with hypothyroidism, and 6 patients with miscellaneous causes of ascites to determine if this albumin difference is indeed a more valuable parameter. Analysis of our data confirms with a larger number of patients that the serum-ascites albumin difference is a more reliable indicator of transudative ascites, better termed portal hypertensive ascites. Malignant ascites without liver metastases had features of nonportal hypertensive ascites, and the serum-ascites albumin difference confirms this. The characteristics of malignant ascites associated with liver metastases, however, resemble those of the portal hypertensive ascites complicating liver disease. This new parameter is also helpful in distinguishing congestive heart failure with high protein ascites and portal hypertensive ascitic features from malignant ascites without liver metastases. Of particular note, myxedematous ascitic fluid, classically categorized as exudative, had an S-A>1.1, indicating the possible role of portal hypertension in the development of ascites in these patients.

KW - ascites, serum-ascites albumin difference

KW - exudate

KW - myxedematous ascites

KW - transudate

UR - http://www.scopus.com/inward/record.url?scp=0023763133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023763133&partnerID=8YFLogxK

U2 - 10.1007/BF01536667

DO - 10.1007/BF01536667

M3 - Article

C2 - 3168691

AN - SCOPUS:0023763133

VL - 33

SP - 1208

EP - 1212

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 10

ER -